APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Amyloidosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Amyloidosis Therapeutics Market Outlook and Growth Opportunities 2026

Report ID 173963200422 December 2025197 pages

Choose your research edition.

Industry ResearchAmyloidosis Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyloidosis Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Amyloidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyloidosis Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyloidosis Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Amyloidosis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Amyloidosis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Amyloidosis Therapeutics market include Pfizer Inc., GlaxoSmithKline Plc, SOM Innovation Biotech SL, Prothena Corporation Plc, ProteoTech, Inc., Onyx Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Celgene Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Amyloidosis Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Amyloidosis Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Amyloidosis Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Amyloidosis Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Amyloidosis Therapeutics Segment by Company

Pfizer Inc.

GlaxoSmithKline Plc

SOM Innovation Biotech SL

Prothena Corporation Plc

ProteoTech, Inc.

Onyx Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Celgene Corporation

Bsim2

Bellus Health Inc.

Arcturus Therapeutics, Inc

Alnylam Pharmaceuticals, Inc.

Amyloidosis Therapeutics Segment by Type

Canakinumab

CAEL-101

ALN-TTRsc02

ALN-ANG

AG-10

Others

Amyloidosis Therapeutics Segment by Application

ATTR Amyloidoses

AL Amyloidosis

AA Amyloidoses

Others

Amyloidosis Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Amyloidosis Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Amyloidosis Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Amyloidosis Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Amyloidosis Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyloidosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Amyloidosis Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Amyloidosis Therapeutics industry.

Chapter 3: Detailed analysis of Amyloidosis Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Amyloidosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Amyloidosis Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Amyloidosis Therapeutics Industry Trends Table 2. Amyloidosis Therapeutics Industry Drivers Table 3. Amyloidosis Therapeutics Industry Opportunities and Challenges Table 4. Amyloidosis Therapeutics Industry Restraints Table 5. Global Amyloidosis Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Amyloidosis Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Amyloidosis Therapeutics Sales Volume by Company (k units) & (2021-2026) Table 8. Global Amyloidosis Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Amyloidosis Therapeutics Average Price (US$/unit) of Company (2021-2026) Table 10. Global Amyloidosis Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Amyloidosis Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Amyloidosis Therapeutics Company, Product Type & Application Table 13. Global Amyloidosis Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Amyloidosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Canakinumab Table 18. Significant Companies of CAEL-101 Table 19. Significant Companies of ALN-TTRsc02 Table 20. Significant Companies of ALN-ANG Table 21. Significant Companies of AG-10 Table 22. Significant Companies of Others Table 23. Global Amyloidosis Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Amyloidosis Therapeutics Sales Volume by Type (2021-2026) & (k units) Table 25. Global Amyloidosis Therapeutics Sales Volume by Type (2027-2032) & (k units) Table 26. Global Amyloidosis Therapeutics Sales Volume Share by Type (2021-2026) Table 27. Global Amyloidosis Therapeutics Sales Volume Share by Type (2027-2032) Table 28. Global Amyloidosis Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Amyloidosis Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Amyloidosis Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Amyloidosis Therapeutics Sales Value Share by Type (2021-2026) Table 32. Global Amyloidosis Therapeutics Sales Value Share by Type (2027-2032) Table 33. Significant Companies of ATTR Amyloidoses Table 34. Significant Companies of AL Amyloidosis Table 35. Significant Companies of AA Amyloidoses Table 36. Significant Companies of Others Table 37. Global Amyloidosis Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Amyloidosis Therapeutics Sales Volume by Application (2021-2026) & (k units) Table 39. Global Amyloidosis Therapeutics Sales Volume by Application (2027-2032) & (k units) Table 40. Global Amyloidosis Therapeutics Sales Volume Share by Application (2021-2026) Table 41. Global Amyloidosis Therapeutics Sales Volume Share by Application (2027-2032) Table 42. Global Amyloidosis Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Amyloidosis Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Amyloidosis Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Amyloidosis Therapeutics Sales Value Share by Application (2021-2026) Table 46. Global Amyloidosis Therapeutics Sales Value Share by Application (2027-2032) Table 47. Global Amyloidosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Amyloidosis Therapeutics Sales by Region (2021-2026) & (k units) Table 49. Global Amyloidosis Therapeutics Sales Market Share by Region (2021-2026) Table 50. Global Amyloidosis Therapeutics Sales by Region (2027-2032) & (k units) Table 51. Global Amyloidosis Therapeutics Sales Market Share by Region (2027-2032) Table 52. Global Amyloidosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Amyloidosis Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Amyloidosis Therapeutics Sales Value Share by Region (2021-2026) Table 55. Global Amyloidosis Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Amyloidosis Therapeutics Sales Value Share by Region (2027-2032) Table 57. Global Amyloidosis Therapeutics Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Amyloidosis Therapeutics Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Amyloidosis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Amyloidosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 62. Global Amyloidosis Therapeutics Sales Market Share by Country (2021-2026) Table 63. Global Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 64. Global Amyloidosis Therapeutics Sales Market Share by Country (2027-2032) Table 65. Global Amyloidosis Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Amyloidosis Therapeutics Sales Value Market Share by Country (2021-2026) Table 67. Global Amyloidosis Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Amyloidosis Therapeutics Sales Value Market Share by Country (2027-2032) Table 69. Pfizer Inc. Company Information Table 70. Pfizer Inc. Business Overview Table 71. Pfizer Inc. Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Pfizer Inc. Amyloidosis Therapeutics Product Portfolio Table 73. Pfizer Inc. Recent Development Table 74. GlaxoSmithKline Plc Company Information Table 75. GlaxoSmithKline Plc Business Overview Table 76. GlaxoSmithKline Plc Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio Table 78. GlaxoSmithKline Plc Recent Development Table 79. SOM Innovation Biotech SL Company Information Table 80. SOM Innovation Biotech SL Business Overview Table 81. SOM Innovation Biotech SL Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio Table 83. SOM Innovation Biotech SL Recent Development Table 84. Prothena Corporation Plc Company Information Table 85. Prothena Corporation Plc Business Overview Table 86. Prothena Corporation Plc Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio Table 88. Prothena Corporation Plc Recent Development Table 89. ProteoTech, Inc. Company Information Table 90. ProteoTech, Inc. Business Overview Table 91. ProteoTech, Inc. Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio Table 93. ProteoTech, Inc. Recent Development Table 94. Onyx Pharmaceuticals, Inc. Company Information Table 95. Onyx Pharmaceuticals, Inc. Business Overview Table 96. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 98. Onyx Pharmaceuticals, Inc. Recent Development Table 99. Millennium Pharmaceuticals, Inc. Company Information Table 100. Millennium Pharmaceuticals, Inc. Business Overview Table 101. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 103. Millennium Pharmaceuticals, Inc. Recent Development Table 104. Isis Pharmaceuticals, Inc. Company Information Table 105. Isis Pharmaceuticals, Inc. Business Overview Table 106. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 108. Isis Pharmaceuticals, Inc. Recent Development Table 109. Celgene Corporation Company Information Table 110. Celgene Corporation Business Overview Table 111. Celgene Corporation Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Celgene Corporation Amyloidosis Therapeutics Product Portfolio Table 113. Celgene Corporation Recent Development Table 114. Bsim2 Company Information Table 115. Bsim2 Business Overview Table 116. Bsim2 Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Bsim2 Amyloidosis Therapeutics Product Portfolio Table 118. Bsim2 Recent Development Table 119. Bellus Health Inc. Company Information Table 120. Bellus Health Inc. Business Overview Table 121. Bellus Health Inc. Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio Table 123. Bellus Health Inc. Recent Development Table 124. Arcturus Therapeutics, Inc Company Information Table 125. Arcturus Therapeutics, Inc Business Overview Table 126. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio Table 128. Arcturus Therapeutics, Inc Recent Development Table 129. Alnylam Pharmaceuticals, Inc. Company Information Table 130. Alnylam Pharmaceuticals, Inc. Business Overview Table 131. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 133. Alnylam Pharmaceuticals, Inc. Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Amyloidosis Therapeutics Distributors List Table 137. Amyloidosis Therapeutics Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Amyloidosis Therapeutics Product Image Figure 2. Global Amyloidosis Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyloidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Amyloidosis Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Amyloidosis Therapeutics Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Amyloidosis Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Canakinumab Image Figure 10. CAEL-101 Image Figure 11. ALN-TTRsc02 Image Figure 12. ALN-ANG Image Figure 13. AG-10 Image Figure 14. Others Image Figure 15. Global Amyloidosis Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Amyloidosis Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Amyloidosis Therapeutics Sales Volume Share by Type (2021-2032) Figure 18. Global Amyloidosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Amyloidosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Amyloidosis Therapeutics Sales Value Share by Type (2021-2032) Figure 21. ATTR Amyloidoses Image Figure 22. AL Amyloidosis Image Figure 23. AA Amyloidoses Image Figure 24. Others Image Figure 25. Global Amyloidosis Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Amyloidosis Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Amyloidosis Therapeutics Sales Volume Share by Application (2021-2032) Figure 28. Global Amyloidosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Amyloidosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Amyloidosis Therapeutics Sales Value Share by Application (2021-2032) Figure 31. Global Amyloidosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Amyloidosis Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Amyloidosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Amyloidosis Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Amyloidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 36. North America Amyloidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Amyloidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Amyloidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Amyloidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Amyloidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Amyloidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 42. South America Amyloidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Amyloidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Amyloidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Amyloidosis Therapeutics Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Amyloidosis Therapeutics Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Canakinumab
  • CAEL-101
  • ALN-TTRsc02
  • ALN-ANG
  • AG-10
  • Others
Applications
  • ATTR Amyloidoses
  • AL Amyloidosis
  • AA Amyloidoses
  • Others
Companies covered
  • Pfizer Inc.
  • GlaxoSmithKline Plc
  • SOM Innovation Biotech SL
  • Prothena Corporation Plc
  • ProteoTech, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • Celgene Corporation
  • Bsim2
  • Bellus Health Inc.
  • Arcturus Therapeutics, Inc
  • Alnylam Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Amyloidosis Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Amyloidosis Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Amyloidosis Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Amyloidosis Therapeutics Market Dynamics
  1. 2.1 Amyloidosis Therapeutics Industry Trends
  2. 2.2 Amyloidosis Therapeutics Industry Drivers
  3. 2.3 Amyloidosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Amyloidosis Therapeutics Industry Restraints
3 Amyloidosis Therapeutics Market by Company
  1. 3.1 Global Amyloidosis Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Amyloidosis Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Amyloidosis Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Amyloidosis Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Amyloidosis Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Amyloidosis Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Amyloidosis Therapeutics Company Product Type and Application
  8. 3.8 Global Amyloidosis Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Amyloidosis Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Amyloidosis Therapeutics Market by Type
  1. 4.1 Amyloidosis Therapeutics Type Introduction
  2. 4.1.1 Canakinumab
  3. 4.1.2 CAEL-101
  4. 4.1.3 ALN-TTRsc02
  5. 4.1.4 ALN-ANG
  6. 4.1.5 AG-10
  7. 4.1.6 Others
  8. 4.2 Global Amyloidosis Therapeutics Sales Volume by Type
  9. 4.2.1 Global Amyloidosis Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Amyloidosis Therapeutics Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Amyloidosis Therapeutics Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Amyloidosis Therapeutics Sales Value by Type
  13. 4.3.1 Global Amyloidosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Amyloidosis Therapeutics Sales Value by Type (2021-2032)
  15. 4.3.3 Global Amyloidosis Therapeutics Sales Value Share by Type (2021-2032)
5 Amyloidosis Therapeutics Market by Application
  1. 5.1 Amyloidosis Therapeutics Application Introduction
  2. 5.1.1 ATTR Amyloidoses
  3. 5.1.2 AL Amyloidosis
  4. 5.1.3 AA Amyloidoses
  5. 5.1.4 Others
  6. 5.2 Global Amyloidosis Therapeutics Sales Volume by Application
  7. 5.2.1 Global Amyloidosis Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Amyloidosis Therapeutics Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Amyloidosis Therapeutics Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Amyloidosis Therapeutics Sales Value by Application
  11. 5.3.1 Global Amyloidosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Amyloidosis Therapeutics Sales Value by Application (2021-2032)
  13. 5.3.3 Global Amyloidosis Therapeutics Sales Value Share by Application (2021-2032)
6 Amyloidosis Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Amyloidosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Amyloidosis Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Amyloidosis Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Amyloidosis Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Amyloidosis Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Amyloidosis Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Amyloidosis Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Amyloidosis Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Amyloidosis Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Amyloidosis Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Amyloidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Amyloidosis Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Amyloidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Amyloidosis Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Amyloidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Amyloidosis Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Amyloidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Amyloidosis Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Amyloidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Amyloidosis Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Amyloidosis Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Amyloidosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Amyloidosis Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Amyloidosis Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Amyloidosis Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Amyloidosis Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Amyloidosis Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Amyloidosis Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Amyloidosis Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Amyloidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Amyloidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer Inc.
  2. 8.1.1 Pfizer Inc. Company Information
  3. 8.1.2 Pfizer Inc. Business Overview
  4. 8.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
  6. 8.1.5 Pfizer Inc. Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 SOM Innovation Biotech SL
  14. 8.3.1 SOM Innovation Biotech SL Company Information
  15. 8.3.2 SOM Innovation Biotech SL Business Overview
  16. 8.3.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
  18. 8.3.5 SOM Innovation Biotech SL Recent Developments
  19. 8.4 Prothena Corporation Plc
  20. 8.4.1 Prothena Corporation Plc Company Information
  21. 8.4.2 Prothena Corporation Plc Business Overview
  22. 8.4.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
  24. 8.4.5 Prothena Corporation Plc Recent Developments
  25. 8.5 ProteoTech, Inc.
  26. 8.5.1 ProteoTech, Inc. Company Information
  27. 8.5.2 ProteoTech, Inc. Business Overview
  28. 8.5.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
  30. 8.5.5 ProteoTech, Inc. Recent Developments
  31. 8.6 Onyx Pharmaceuticals, Inc.
  32. 8.6.1 Onyx Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Onyx Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  36. 8.6.5 Onyx Pharmaceuticals, Inc. Recent Developments
  37. 8.7 Millennium Pharmaceuticals, Inc.
  38. 8.7.1 Millennium Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Millennium Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  42. 8.7.5 Millennium Pharmaceuticals, Inc. Recent Developments
  43. 8.8 Isis Pharmaceuticals, Inc.
  44. 8.8.1 Isis Pharmaceuticals, Inc. Company Information
  45. 8.8.2 Isis Pharmaceuticals, Inc. Business Overview
  46. 8.8.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  48. 8.8.5 Isis Pharmaceuticals, Inc. Recent Developments
  49. 8.9 Celgene Corporation
  50. 8.9.1 Celgene Corporation Company Information
  51. 8.9.2 Celgene Corporation Business Overview
  52. 8.9.3 Celgene Corporation Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Celgene Corporation Amyloidosis Therapeutics Product Portfolio
  54. 8.9.5 Celgene Corporation Recent Developments
  55. 8.10 Bsim2
  56. 8.10.1 Bsim2 Company Information
  57. 8.10.2 Bsim2 Business Overview
  58. 8.10.3 Bsim2 Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bsim2 Amyloidosis Therapeutics Product Portfolio
  60. 8.10.5 Bsim2 Recent Developments
  61. 8.11 Bellus Health Inc.
  62. 8.11.1 Bellus Health Inc. Company Information
  63. 8.11.2 Bellus Health Inc. Business Overview
  64. 8.11.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
  66. 8.11.5 Bellus Health Inc. Recent Developments
  67. 8.12 Arcturus Therapeutics, Inc
  68. 8.12.1 Arcturus Therapeutics, Inc Company Information
  69. 8.12.2 Arcturus Therapeutics, Inc Business Overview
  70. 8.12.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
  72. 8.12.5 Arcturus Therapeutics, Inc Recent Developments
  73. 8.13 Alnylam Pharmaceuticals, Inc.
  74. 8.13.1 Alnylam Pharmaceuticals, Inc. Company Information
  75. 8.13.2 Alnylam Pharmaceuticals, Inc. Business Overview
  76. 8.13.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  78. 8.13.5 Alnylam Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Amyloidosis Therapeutics Value Chain Analysis
  2. 9.1.1 Amyloidosis Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Amyloidosis Therapeutics Sales Mode & Process
  6. 9.2 Amyloidosis Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Amyloidosis Therapeutics Distributors
  9. 9.2.3 Amyloidosis Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst